Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Sanofi took extra time on Tuesday to offer an upbeat assessment of its top-line results for a pivotal study of a new ERT for late-onset Pompe disease. But with Amicus breathing down its neck with a Phase III rival of its own, the pharma giant was treated to some unwelcome reviews from a slate of analysts covering the matchup.
“Meh,” summed up Cowen’s Ritu Baral in the headline, which helps explain why Amicus’ stock shot up 17%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.